NCT07115667View on ClinicalTrials.gov

Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions
Solitary Bone PlasmacytomaPlasmacytoma of BonePlasma Cell Disorders
Interventions
DRUG

BCMA/CD3 bispecific antibody (CM336)

Patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration will receive radiation combined with a BCMA/CD3 bispecific antibody (CM336)

Trial Locations (1)

300020

RECRUITING

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT07115667 - Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration | Biotech Hunter | Biotech Hunter